Merck (MRK)
$92.13
0.12 (0.13%)
MRK Stock Quote Delayed 30 Minutes
Hottest Healthcare Stocks Now – CLVS KND ACAD QGEN
Healthcare stocks declined on Wall Street so far on Thursday, down 0.8%. NASDAQ:CLVS, NYSE:KND, NASDAQ:ACAD, NASDAQ:QGEN, NASDAQ:QCOR, NYSE:AZN, NYSE:ZMH, NYSE:OPK, NYSE:PRGO, NYSE:ABBV, NYSE:WX, NASDAQ:CLDX, NASDAQ:INCY, NYSE:PBYI, NYSE:BMY, NASDAQ:SGEN, NASDAQ:CBST, NASDAQ:LGND, NASDAQ:NEOG, NASDAQ:ACHC
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
$90.58
Market Cap
233.03B
PE Ratio
13.68
EPS
6.7363
Volume (Avg. Vol.)
14.13M
Day's Range
$90.71 - $92.35
52-Week Range
$81.04 - $132.70
Dividend & Yield
$3.12 (3.39%)
MRK Stock Predictions, Articles, and Merck News
MRK: Merck Sells Consumer Business to Double Down on Blockbusters
Swinging for the fences, MRK sold one of the industry's crown jewels in exchange for an opportunity to find new blockbuster drugs. It's a risky strategy that had better pay off for MRK shareholders.
4 Big-Name Spinoffs We Might See Soon
They aren't the market's most-discussed potential spinoffs, but that's why they may hold the most upside ... the hidden value is yet to be priced in.
Biggest Movers in Healthcare Stocks Now – HTWR ENDP WMGI ICLR
Healthcare stocks fell broadly on Wall Street on Thursday morning, with the sector seeing an overall decline of 0.1%. NASDAQ:HTWR, NASDAQ:ENDP, NASDAQ:WMGI, NASDAQ:ICLR, NYSE:TEVA, NASDAQ:MYL, NYSE:ACT, NYSE:GB, NYSE:MRK, NASDAQ:SHPG, NASDAQ:MASI, NYSE:CAH, NASDAQ:MYGN, NASDAQ:XLRN, NASDAQ:NBIX, NASDAQ:CLDX, NASDAQ:ACHC, NYSE:WST, NASDAQ:NEOG, NASDAQ:INCY
FDA Considers Giving OK for OTC Singulair
Drug company Merck is looking for approval from the Food and Drug Administration to start selling its Singulair over the counter.
Hottest Healthcare Stocks Now – IRWD CBST INCY NPSP
Healthcare stocks advanced 0.2% on Wall Street on Tuesday morning. NASDAQ:IRWD, NASDAQ:CBST, NASDAQ:INCY, NASDAQ:NPSP, NYSE:MRK, NASDAQ:UTHR, NASDAQ:QCOR, NYSE:AZN, NASDAQ:KERX, NYSE:OPK, NASDAQ:SHPG, NYSE:BSX, NYSE:BMY, NYSE:HCA, NYSE:HLS, NYSE:OMI, NYSE:CYH, NYSE:HAE, NYSE:PBYI, NYSE:PFE
Hottest Basic Materials Stocks Now – SIAL GPK SMG FOE
Basic materials stocks fell broadly 0.4% on Wall Street so far on Thursday. NASDAQ:SIAL, NYSE:GPK, NYSE:SMG, NYSE:FOE, NYSE:FCX, NASDAQ:MEOH, AMEX:NG, NYSE:CLW, NYSE:SSL, NASDAQ:MATW, NYSE:NEU, NYSE:FBR, NYSE:CRS, NYSE:HMY, NASDAQ:KALU, NYSE:RS, NASDAQ:GPRE, NYSE:NUE, NYSE:SQM, NYSE:NEM
Biggest Movers in Healthcare Stocks Now – ALXN MRK GILD XRAY
Healthcare stocks declined on Wall Street so far on Thursday, down 0.2%. NASDAQ:ALXN, NYSE:MRK, NASDAQ:GILD, NASDAQ:XRAY, NASDAQ:XLRN, NYSE:TEVA, NYSE:SNY, NASDAQ:SIRO, NASDAQ:HSIC, NASDAQ:IDXX, NASDAQ:ACAD, NASDAQ:ALNY, NASDAQ:PCRX, NASDAQ:NBIX, NYSE:WCG, NASDAQ:CLVS, NYSE:CNC, NASDAQ:NKTR, NASDAQ:KERX, NYSE:LCI
Grass Pollen Allergy? New Grastek Pill From Merck Hits Shelves Soon
Merck says the U.S. Food and Drug Administration has approve the release of its Grastek grass pollen allergy drug, which will launch later this month.
Hottest Healthcare Stocks Now – WMGI PDLI GB MRK
Healthcare stocks declined broadly on Wall Street on Thursday morning, with the sector seeing an overall decline of 0.2%. NASDAQ:WMGI, NASDAQ:PDLI, NYSE:GB, NYSE:MRK, NASDAQ:SHPG, NASDAQ:ISRG, NYSE:WX, NYSE:TEVA, NASDAQ:ARTC, NYSE:CVD, NASDAQ:CLVS, NASDAQ:ALNY, NASDAQ:NKTR, NASDAQ:ALXN, NASDAQ:SGMO, NASDAQ:ISIS, NASDAQ:NBIX, NASDAQ:BMRN, NASDAQ:IMGN, NASDAQ:NPSP
5 Biotech Stocks Promising Future Rewards
Biotech is one of the dynamic sectors in our economy, and in the stock market as well. These 5 biotech stocks are solid buys in our Portfolio Grader model.
5 Pharmaceutical Stocks to Buy Now
The grades of five pharmaceutical stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an "A" ("strong buy") or "B" overall ("buy") rating.
8 Pharmaceutical Stocks to Buy Now
The grades of eight pharmaceutical stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an "A" ("strong buy") or "B" overall ("buy") rating.
52 Trades to Beat the Mutual Fund Slump
I've taken some of the guesswork out of stock picking for you by updating my ratings for these 52 stocks.
5 Not-So-Crazy Blue-Chip Spinoffs
Here are some not-so-crazy spinoff ideas we might see in 2014 as some big-name blue chips look to streamline operations and align strategy with structure.
8 Pharmaceutical Stocks to Buy Now
The grades of eight pharmaceutical stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").
Healthcare Stocks: No Longer a Sure Thing
Healthcare stocks have outperformed in recent years, but investors need to be selective with valuations that now are at richer levels.
Top 10 Dow Dividend Stocks for January
The market rally is getting more selective as we go deeper into 2014. Stick with these safe dividend stocks that have a history of dependable payouts.
MRK: Merck Stock a Strong Performer In the Pharma Space
Merck is one the most high profile companies in the pharmaceutical industry, and Merck stock is well worth a look for investors. I rate it a buy today.
33 Trades To Combat the Chill on Wall Street
It's a New Year, and it to me it shapes up as another good one. However investors still need to work portfolios, and here are 33 recent upgrades and downgrades
The S&P’s Most Dramatic Performances of 2013 (And What They Taught Us)
We look at 2013's best and worst performers in the S&P 500, as well as what that might say about returns in 2014.
